The Department of Orbital and Oculoplastic Surgery, The Eye Hospital of Wenzhou Medical University, Wenzhou, P.R. China.
Laryngoscope. 2022 Sep;132(9):1743-1749. doi: 10.1002/lary.30131. Epub 2022 Apr 6.
To investigate the feasibility, efficacy, and safety of an endoscopic transethmoidal-sphenoidal approach in removing a small cavernous hemangioma (CH) located in the deep lateral orbital apex.
This study involved 19 patients diagnosed with a CH located in the deep lateral orbital apex. All patients underwent an endoscopic transethmoidal-sphenoidal approach for removal of the CH. The best-corrected visual acuity (BCVA), visual field, and surgery-related complications were analyzed and compared.
All tumors in this study were completely removed. The mean BCVA was LogMAR 0.97 ± 0.97 preoperatively and LogMAR 0.38 ± 0.64 postoperatively (p < 0.05). The mean visual field index was 52.26% ± 33.26% preoperatively and 75.47% ± 30.49% postoperatively (p < 0.05). The mean deviation index was -17.48 ± 12.43 dB preoperatively and -10.10 ± 10.85 dB postoperatively (p < 0.05), and the pattern standard deviation was 6.37 ± 3.77 dB preoperatively and 4.90 ± 3.56 dB postoperatively (p > 0.05). Four (21.1%) patients developed oculomotor limitations and two (10.5%) patients developed ptosis after surgery. All of these symptoms resolved spontaneously, and no other complications occurred. The mean follow-up time was 6.71 ± 3.89 months.
The endoscopic transethmoidal-sphenoidal approach is an effective and minimally invasive treatment for removing small CH in the deep lateral orbital apex.
4 Laryngoscope, 132:1743-1749, 2022.
探讨经鼻内镜-蝶窦入路切除位于眶深部外侧尖部小海绵状血管瘤（CH）的可行性、疗效和安全性。
本研究纳入 19 例诊断为位于眶深部外侧尖部 CH 的患者。所有患者均采用经鼻内镜-蝶窦入路切除 CH。分析比较最佳矫正视力（BCVA）、视野和与手术相关的并发症。
本研究所有肿瘤均完全切除。术前平均 BCVA 为 LogMAR 0.97±0.97，术后为 LogMAR 0.38±0.64（p<0.05）。术前平均视野指数为 52.26%±33.26%，术后为 75.47%±30.49%（p<0.05）。术前平均平均偏差指数为-17.48±12.43 dB，术后为-10.10±10.85 dB（p<0.05），模式标准差术前为 6.37±3.77 dB，术后为 4.90±3.56 dB（p>0.05）。术后 4 例（21.1%）患者出现动眼神经受限，2 例（10.5%）患者出现上睑下垂。所有这些症状均自发缓解，无其他并发症发生。平均随访时间为 6.71±3.89 个月。
经鼻内镜-蝶窦入路是治疗眶深部外侧尖部小 CH 的有效、微创方法。
4 级《喉镜》，132：1743-1749，2022 年。
